Former executives from some of Canada’s largest cannabis companies are pioneering the psychedelic drug industry.
Toronto-based MindMed plans to test microdosed LSD as a treatment for ADHD and a molecule derived from the psychoactive compound Ibogaine as a treatment for opioid addiction. (Ibogaine is a psychoactive compound found in Iboga, a shrub native to West Africa.)
Globe and Mail
- MindMed has raised C$6.2M from investors including former Canopy Growth CEO Bruce Linton and “Shark Tank’s” Kevin O’Leary.
- Toronto-based Field Trip Ventures hopes to develop a “clinic model for psychedelics.”
- Insiders say the skills executives developed in the cannabis industry such as plant cultivation and dealing with regulations are relevant to psychedelics.
- A study found people who microdose psychedelics are “commonly doing so as a self-managed therapy for mental health.“